Semaglutide Protocol
Dosing & Research
Last Updated: April 22, 2026
Weight-loss and diabetes research, Appetite regulation, Cardiometabolic outcomes, GLP-1 pharmacology
Evidence Level
Human Clinical Data Available
Species Studied
Human • Rat • Mouse
Half-Life
Approximately 7 Days
Administration
Subcutaneous
Frequency
Once Or Twice Weekly, Same Day(s) Each Week
How It Works
- Weight-loss and diabetes research
- Appetite regulation
- Cardiometabolic outcomes
- GLP-1 pharmacology
Dosing Structure
Dose
0.25–2.0 mg weekly
Frequency
Once Or Twice Weekly, Same Day(s) Each Week
Notes
1x Weekly titration: Week 1-4: 0.25mg | Week 5-8: 0.5mg | Week 9-12: 1mg | Week 13-16: 1.7mg | Week 17+: 2.4mg. 2x Weekly titration: Week 1-4: 0.125mg | Week 5-8: 0.25mg | Week 9-12: 0.5mg | Week 13-16: 0.85mg | Week 17+: 1.2mg. No need to increase dose if experiencing benefits at a lower dose. Inject: Abdomen, thigh, or upper arm (rotate weekly). Any time of day, with or without food. Typically follows a weekly titration schedule.
Example Protocols
Dose: 0.25–2.0 mg weekly
Frequency: Once Or Twice Weekly, Same Day(s) Each Week
Duration: 8-48 weeks
Off Period: Not listed
Protocol Notes
1x Weekly titration
Week 1-4: 0.25mgWeek 5-8: 0.5mgWeek 9-12: 1mgWeek 13-16: 1.7mgWeek 17+: 2.4mg
2x Weekly titration
Week 1-4: 0.125mgWeek 5-8: 0.25mgWeek 9-12: 0.5mgWeek 13-16: 0.85mgWeek 17+: 1.2mg
•
No need to increase dose if experiencing benefits at a lower dose.
•
Inject: Abdomen, thigh, or upper arm (rotate weekly).
•
Any time of day, with or without food.
•
Typically follows a weekly titration schedule.
Research & Studies
Loading citations…
- Curated References
- CuratedPubMedPMID 34853213Once-Weekly Semaglutide in Adults with Overweight or Obesity↗N Engl J Med · 2021 · Wilding JPH, Batterham RL, Calanna S, et al.dosingobesityphase-3
- CuratedPubMedPMID 29677150Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes↗N Engl J Med · 2016 · Marso SP, Bain SC, Consoli A, et al.cardiovascularsafetyphase-3
- CuratedPubMedPMID 35658048Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials↗Obesity · 2020 · Kushner RF, Calanna S, Davies M, et al.dosingmechanism
- CuratedPubMedPMID 31693900Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes↗N Engl J Med · 2019 · Husain M, Birkenfeld AL, Donsmark M, et al.oralcardiovascularT2D
Research Feedback
0 approved
For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.
Be the first to submit research feedback for this peptide.
Approved submissions will appear here as aggregated insights.